Synergistic interactions between selective pharmacological inhibitors of phosphodiesterase isozyme families PDE III and PDE IV to attenuate proliferation of rat vascular smooth muscle cells
- 17 August 1994
- journal article
- research article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 48 (4) , 827-835
- https://doi.org/10.1016/0006-2952(94)90062-0
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Isoenzyme selective phosphodiesterase inhibitors: potential clinical uses.British Journal of Clinical Pharmacology, 1993
- Regulation and function of cyclic nucleotidesCurrent Opinion in Cell Biology, 1992
- Phosphodiesterase inhibitors: new opportunities for the treatment of asthma.Thorax, 1991
- Prolactin induces proliferation of vascular smooth muscle cells through a protein kinase C‐dependent mechanismJournal of Cellular Physiology, 1991
- Cyclic nucleotide phosphodiesterases: Pharmacology, biochemistry and functionPharmacology & Therapeutics, 1991
- Cell-free stimulation of the insulin-sensitive cAMP phosphodiesterase by the joint actions of ATP and the soluble fraction from insulin-treated rat liverBiochemical and Biophysical Research Communications, 1990
- Syndromes of accelerated atherosclerosis: Role of vascular injury and smooth muscle cell proliferationJournal of the American College of Cardiology, 1990
- Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitorsTrends in Pharmacological Sciences, 1990
- Adenosine receptor‐mediated changes in cyclic AMP production and DNA synthesis in cultured arterial smooth muscle cellsJournal of Cellular Physiology, 1985
- Characterization of two putative smooth muscle cell lines from rat thoracic aortaExperimental Cell Research, 1976